Edition:
United States

Oasmia Pharmaceutical AB (OASM.OQ)

OASM.OQ on NASDAQ Stock Exchange Capital Market

1.51USD
18 May 2018
Change (% chg)

-- (--)
Prev Close
$1.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,697
52-wk High
$3.10
52-wk Low
$0.80

Chart for

About

Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology. The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. The Animal Health area focuses on developing cancer... (more)
No analyst recommendations are available for .

Overall

Beta: 0.76
Market Cap(Mil.): kr748.69
Shares Outstanding(Mil.): 176.41
Dividend: --
Yield (%): --

Financials

  OASM.OQ Industry Sector
P/E (TTM): -- 28.57 32.53
EPS (TTM): -0.88 -- --
ROI: -38.38 13.08 12.63
ROE: -38.37 14.80 14.50

BRIEF-Oasmia Pharmaceutical Q3 sales rise, smaller operating loss

* Q3 ‍CONSOLIDATED NET SALES AMOUNTED TO TSEK 656 COMPARED TO TSEK 36 IN Q3 PREVIOUS YEAR​

Mar 02 2018

BRIEF-Oasmia Pharma says all patients have been treated in two ongoing studies with Docecal

* REG-OASMIA PHARMACEUTICAL’S DOCECAL PROGRAM ACHIEVES SIGNIFICANT DEVELOPMENT MILESTONE

Feb 19 2018

BRIEF-Oasmia receives marketing approval for Paclical in Kazakhstan

* OASMIA PHARMACEUTICAL RECEIVES MARKETING APPROVAL FOR PACLICAL® IN KAZAKHSTAN Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Dec 11 2017

BRIEF-Oasmia Pharmaceutical Q2 operating loss shrinks

* OASMIA PHARMACEUTICAL AB Q2 ‍CONSOLIDATED NET SALES AMOUNTED TO TSEK 1,651 COMPARED TO TSEK 56 IN THE SECOND QUARTER THE PREVIOUS YEAR ​

Dec 01 2017

BRIEF-Oasmia completes 28 mln SEK private placement of new convertible instruments

* OASMIA HAS COMPLETED A PRIVATE PLACEMENT OF NEW CONVERTIBLE INSTRUMENTS IN A TOTAL AMOUNT OF SEK 28,000,000

Nov 30 2017

Earnings vs. Estimates